Sign up
Pharma Capital

Zelda Therapeutics trade higher on medical cannabis focus

Shares have nearly tripled since the reverse takeover in late 2016.
TyraT-4_10_14_124.jpg
The company has a solid pipeline of news flow in 2017

Zelda Therapeutics (ASX:ZLD) shares have continued their strong run in 2017 trading up over 85% year to date to $0.074.

This also means that the medical cannabis company’s share price has nearly tripled since listing on the Australian Stock Exchange in November, 2016 at $0.025.

Zelda is an Australian-based bio-pharmaceutical company that has secured exclusive, global access to an extensive set of human data related to medicinal cannabis.

This human data has been generated over several years by a California-based group that has a high profile within the U.S. and a growing international profile.

Zelda has embarked on a program of human clinical trials initially in sleep disorder (insomnia) and eczema indications.

In addition, Zelda is building a pre-clinical research portfolio targeting cancer.

The company expects to be commencing these trials during 2017 and have identified a relatively rapid path to commercialisation.

If successful, this could see Zelda obtaining product registrations in selected markets in 2018 with revenues flowing from there.



Register here to be notified of future Company articles
View full profile

Timeline

View All

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.